HC Wainwright set a $8.00 price target on Agile Therapeutics (NASDAQ:AGRX) in a research report report published on Wednesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other equities research analysts also recently weighed in on the stock. Noble Financial reaffirmed a buy rating on shares of Agile Therapeutics in a research report on Wednesday, March 14th. ValuEngine raised shares of Agile Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $9.00.
Shares of AGRX traded down $0.03 during midday trading on Wednesday, hitting $2.74. The company had a trading volume of 940 shares, compared to its average volume of 79,739. The company has a market capitalization of $96.93 million, a P/E ratio of -2.97 and a beta of 2.12. Agile Therapeutics has a 52 week low of $2.72 and a 52 week high of $2.75.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Monday, March 12th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.05. sell-side analysts expect that Agile Therapeutics will post -0.71 earnings per share for the current year.
Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in shares of Agile Therapeutics by 113.1% in the 4th quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 20,654 shares during the period. Franklin Resources Inc. raised its stake in shares of Agile Therapeutics by 3.4% in the 4th quarter. Franklin Resources Inc. now owns 2,867,800 shares of the specialty pharmaceutical company’s stock valued at $7,714,000 after buying an additional 95,600 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Agile Therapeutics in the 3rd quarter valued at $467,000. Renaissance Technologies LLC raised its stake in shares of Agile Therapeutics by 313.7% in the 4th quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock valued at $985,000 after buying an additional 277,600 shares in the last quarter. Finally, Broadfin Capital LLC acquired a new position in shares of Agile Therapeutics in the 4th quarter valued at $964,000. 70.84% of the stock is owned by institutional investors and hedge funds.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.